Equities
Health CareMedical Equipment and Services
  • Price (SEK)270.00
  • Today's Change-2.25 / -0.83%
  • Shares traded19.05k
  • 1 Year change+92.50%
  • Beta1.2147
Data delayed at least 15 minutes, as of Nov 22 2024 09:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in SEK

The 3 analysts offering 12 month price targets for Sectra AB have a median target of 240.00, with a high estimate of 330.00 and a low estimate of 115.00. The median estimate represents a -11.85% decrease from the last price of 272.25.
High21.2%330.00
Med-11.8%240.00
Low-57.8%115.00

Dividends

Historical dividend information is not available for Sectra AB.
Div growth (TTM)--
More ▼

Earnings history & estimates in SEK

On Sep 06, 2024, Sectra AB reported 1st quarter 2025 earnings of 0.42 per share. This result was in line with the expectation of the one analyst following the company and exceeded last year's 1st quarter results by 31.25%.
The next earnings announcement is expected on Dec 12, 2024.
Average growth rate+51.69%
Sectra AB reported annual 2024 earnings of 2.22 per share on Jun 05, 2024.
Average growth rate+16.02%
More ▼

Revenue history & estimates in SEK

Sectra AB (publ) had 1st quarter 2025 revenues of 723.84m. This missed the 729.00m estimate of the one analyst following the company. This was 24.00% above the prior year's 1st quarter results.
Average growth rate+8.26%
Sectra AB (publ) had revenues for the full year 2024 of 2.96bn. This was 26.07% above the prior year's results.
Average growth rate+16.09%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.